Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Raymond Jumps 4% on Ex-BEL Chief’s Defence Appointment
• Supriya Lifescience Falls 12% on NDPS Act Proceedings
• Radico Hits Record High as Magic Moments Sales Soar 43%
• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.